Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

DNL126

Other · developed by Denali Therapeutics

Phase 1/2 Most advanced trial

DNLI Developer

1 Registered trials

What is DNL126?

DNL126 is an intravenously administered repeating-dose agent studied in mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Metabolic
Developer: Denali Therapeutics Inc. (DNLI)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06181136	Phase 1/2	Mucopolysaccharidosis Type IIIA	Active not recruiting	DNLI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mucopolysaccharidosis Type IIIA

More from Denali Therapeutics

Tividenofusp Alfa FDA approved DNL201 Phase 1 DNL343 Phase 2/3 DNL593 Phase 1/2 DNL628 Phase 1 DNL747 Phase 1 DNL919 Phase 1 DNL921 Phase 1 DNL952 Phase 1

Sources

ClinicalTrials.gov NCT06181136

Updated Oct 11, 2026. Something wrong or missing? Report it on the DNLI page.

Follow DNLI, the company behind DNL126

See DNLI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DNLI catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z